.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077132

« Back to Dashboard
NDA 077132 describes RISEDRONATE SODIUM, which is a drug marketed by Teva Pharms Usa, Macleods Pharms Ltd, Aurobindo Pharma Ltd, Apotex Inc, Mylan Pharms Inc, and Sun Pharma Global, and is included in nine NDAs. It is available from seven suppliers. Additional details are available on the RISEDRONATE SODIUM profile page.

The generic ingredient in RISEDRONATE SODIUM is risedronate sodium. There are nineteen drug master file entries for this compound. Eleven suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the risedronate sodium profile page.

Summary for NDA: 077132

Tradename:
RISEDRONATE SODIUM
Applicant:
Teva Pharms Usa
Ingredient:
risedronate sodium
Patents:0
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 077132

Ingredient-typeDiphosphonates

Suppliers and Packaging for NDA: 077132

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL 077132 ANDA Teva Pharmaceuticals USA Inc 0093-3098 0093-3098-29 12 BLISTER PACK in 1 CARTON (0093-3098-29) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0093-3098-19)
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL 077132 ANDA Teva Pharmaceuticals USA Inc 0093-3098 0093-3098-44 4 BLISTER PACK in 1 CARTON (0093-3098-44) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0093-3098-19)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Oct 5, 2007TE:ABRLD:No
Regulatory Exclusivity Expiration:Nov 28, 2015
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Oct 5, 2007TE:ABRLD:No
Regulatory Exclusivity Expiration:Nov 28, 2015
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength35MG
Approval Date:Oct 5, 2007TE:ABRLD:No
Regulatory Exclusivity Expiration:Nov 28, 2015
Regulatory Exclusivity Use:PATENT CHALLENGE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc